Dr. Reddys Launched A Generic Version Of Nexavar (Sorafenib):
As a kinase inhibitor, sorafenib is used to treat unresectable hepatocellular carcinoma and locally recurrent or metastatic, progressively differentiated thyroid carcinoma (DTC), refractory to radioactive iodine treatment.
Dr. Reddy’s Laboratories recently launched Dr. Reddy’s Sorafenib Tablets, USP, 200 mg in the US market, following approval from the US Food and Drug Administration (USFDA.
As a therapeutic substitute for Nexavar (sorafenib) Tablets in the US market, Dr. Reddy’s Laboratories has launched Dr. Reddy’s Sorafenib Tablets, USP, 200 mg following approval by the US Food and Drug Administration (USFDA
Also Read:
- What are the types of Root Cause Analysis (RCA)
- OOS Investigation checkpoints
- What is Clinical Trial?
- What is Phase 0 clinical trial?
Refer YT Channel: Pharmabeej
